Catalent, a global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics, cell and gene therapies and consumer health products, has signed a commercial supply agreement with Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, for its lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB).   P-...